EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions
EYPT Stock Forecast
EyePoint Pharmaceuticals stock forecast is as follows: an average price target of $30.00 (represents a 229.67% upside from EYPT’s last price of $9.10) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
EYPT Price Target
The average price target for EyePoint Pharmaceuticals (EYPT) is $30.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 229.67% upside from EYPT's last price of $9.10.
EYPT Analyst Ratings
According to 6 Wall Street analysts, EyePoint Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for EYPT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
EyePoint Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Yi Chen | H.C. Wainwright | $30.00 | $12.17 | 146.51% | 229.67% |
| May 07, 2024 | Graig Suvannavejh | Mizuho Securities | $30.00 | $11.20 | 167.86% | 229.67% |
| Aug 04, 2022 | - | H.C. Wainwright | $25.00 | $10.22 | 144.62% | 174.73% |
The latest EyePoint Pharmaceuticals stock forecast, released on May 13, 2024 by Yi Chen from H.C. Wainwright, set a price target of $30.00, which represents a 146.51% increase from the stock price at the time of the forecast ($12.17), and a 229.67% increase from EYPT last price ($9.10).
EyePoint Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $30.00 |
| Last Closing Price | $9.10 | $9.10 | $9.10 |
| Upside/Downside | -100.00% | -100.00% | 229.67% |
In the current month, the average price target of EyePoint Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to EyePoint Pharmaceuticals's last price of $9.10. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Jefferies | - | Buy | Initialise |
| Aug 13, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| Aug 13, 2024 | J.P. Morgan | Buy | Buy | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 26, 2024 | Laidlaw | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| May 07, 2024 | Mizuho Securities | Buy | Buy | Hold |
| Mar 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
EyePoint Pharmaceuticals's last stock rating was published by Jefferies on Aug 28, 2024. The company Initialise its EYPT rating from "null" to "Buy".
EyePoint Pharmaceuticals Financial Forecast
EyePoint Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $9.11M | $7.68M | $10.53M | $10.01M | $11.56M | $9.29M | $11.54M | $9.06M | $9.01M | $7.32M | $7.13M | $15.70M | $4.12M | $7.49M | $8.63M | $2.51M | $7.21M | $2.01M | $486.00K | $928.00K |
| Avg Forecast | $600.00K | $533.33K | $6.97M | $7.20M | $9.84M | $9.91M | $10.63M | $9.91M | $8.90M | $7.86M | $79.10M | $7.60M | $10.40M | $10.93M | $10.86M | $9.89M | $9.79M | $9.88M | $8.71M | $7.89M | $18.29M | $13.32M | $3.79M | $7.25M | $7.18M | $3.93M | $6.69M | $3.39M | $165.68K | $806.00K |
| High Forecast | $600.00K | $533.33K | $6.97M | $7.20M | $9.84M | $16.43M | $10.63M | $9.91M | $14.67M | $7.86M | $79.10M | $7.60M | $10.40M | $10.93M | $10.86M | $13.17M | $13.05M | $13.17M | $11.60M | $10.51M | $24.38M | $17.75M | $5.05M | $9.67M | $9.56M | $5.24M | $8.92M | $4.52M | $198.82K | $967.20K |
| Low Forecast | $600.00K | $533.33K | $6.97M | $7.20M | $9.84M | $5.72M | $10.63M | $9.91M | $705.37K | $7.86M | $79.10M | $7.60M | $10.40M | $10.93M | $10.86M | $7.51M | $7.44M | $7.51M | $6.61M | $5.99M | $13.89M | $10.12M | $2.88M | $5.51M | $5.45M | $2.99M | $5.08M | $2.57M | $132.54K | $644.80K |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 6 | 3 | 6 | 5 | 10 | 8 | 4 | 4 | 8 | 6 | 11 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.12% | 1.01% | 1.01% | 0.92% | 1.06% | 0.94% | 1.18% | 0.92% | 1.03% | 0.93% | 0.39% | 1.18% | 1.09% | 1.03% | 1.20% | 0.64% | 1.08% | 0.59% | 2.93% | 1.15% |
EyePoint Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 5 analysts is $7.86M, with a low forecast of $7.86M, and a high forecast of $7.86M. EYPT's average Quarter revenue forecast represents a -13.63% decrease compared to the company's last Quarter revenue of $9.11M (Jun 23).
EyePoint Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 6 | 3 | 6 | 5 | 10 | 8 | 4 | 4 | 8 | 6 | 11 | 20 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-22.76M | $-20.35M | $-21.77M | $-17.14M | $-18.24M | $-17.53M | $-17.35M | $-14.61M | $-7.95M | $-10.25M | $-12.97M | $-1.29M | $-10.47M | $-10.74M | $-7.97M | $-13.23M | $-9.25M | $-17.56M | $-31.65M | $-6.93M |
| Avg Forecast | $-600.00K | $-533.33K | $-6.97M | $-7.20M | $-9.84M | $-9.91M | $-10.63M | $-17.26M | $-8.90M | $-7.86M | $-79.10M | $-18.46M | $-10.40M | $-12.31M | $-10.86M | $-19.74M | $-9.79M | $-11.19M | $-9.72M | $-9.36M | $-18.29M | $-1.29M | $-10.47M | $-9.67M | $-7.18M | $-12.29M | $-10.02M | $-11.04M | $-29.54M | $-5.87M |
| High Forecast | $-600.00K | $-533.33K | $-6.97M | $-7.20M | $-9.84M | $-5.72M | $-10.63M | $-13.81M | $-705.37K | $-7.86M | $-79.10M | $-14.77M | $-10.40M | $-9.85M | $-10.86M | $-15.80M | $-7.44M | $-8.95M | $-7.77M | $-7.49M | $-13.89M | $-1.04M | $-8.38M | $-7.73M | $-5.45M | $-9.83M | $-8.02M | $-8.83M | $-23.63M | $-4.69M |
| Low Forecast | $-600.00K | $-533.33K | $-6.97M | $-7.20M | $-9.84M | $-16.43M | $-10.63M | $-20.71M | $-14.67M | $-7.86M | $-79.10M | $-22.15M | $-10.40M | $-14.77M | $-10.86M | $-23.69M | $-13.05M | $-13.43M | $-11.66M | $-11.23M | $-24.38M | $-1.55M | $-12.57M | $-11.60M | $-9.56M | $-14.74M | $-12.02M | $-13.24M | $-35.45M | $-7.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.29% | 1.10% | 2.09% | 1.39% | 1.68% | 0.89% | 1.77% | 1.31% | 0.82% | 1.10% | 0.71% | 1.00% | 1.00% | 1.11% | 1.11% | 1.08% | 0.92% | 1.59% | 1.07% | 1.18% |
undefined analysts predict EYPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than EyePoint Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
EyePoint Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 6 | 3 | 6 | 5 | 10 | 8 | 4 | 4 | 8 | 6 | 11 | 20 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-22.92M | $-21.59M | $-64.15M | $-18.44M | $-19.60M | $-22.54M | $-20.82M | $-16.70M | $-10.01M | $-12.28M | $-15.47M | $-3.80M | $-12.95M | $-13.17M | $-10.41M | $-15.65M | $-11.50M | $-19.24M | $-33.13M | $-6.98M |
| Avg Forecast | $-46.82M | $-43.50M | $-37.91M | $-35.25M | $-32.63M | $-29.57M | $-26.84M | $-18.97M | $-25.88M | $-26.47M | $73.64M | $-20.29M | $-32.46M | $-14.07M | $-27.69M | $-21.70M | $-22.26M | $-12.79M | $-12.23M | $-11.21M | $-2.88M | $-3.80M | $-12.95M | $-11.86M | $-49.55M | $-14.53M | $-12.46M | $-12.09M | $-30.92M | $-5.90M |
| High Forecast | $-46.82M | $-43.50M | $-37.91M | $-35.25M | $-32.63M | $-22.75M | $-26.84M | $-15.18M | $-17.25M | $-26.47M | $73.64M | $-16.23M | $-32.46M | $-11.25M | $-27.69M | $-17.36M | $-15.30M | $-10.23M | $-9.79M | $-8.97M | $-1.98M | $-3.04M | $-10.36M | $-9.49M | $-34.05M | $-11.62M | $-9.96M | $-9.67M | $-24.73M | $-4.72M |
| Low Forecast | $-46.82M | $-43.50M | $-37.91M | $-35.25M | $-32.63M | $-38.10M | $-26.84M | $-22.76M | $-32.78M | $-26.47M | $73.64M | $-24.35M | $-32.46M | $-16.88M | $-27.69M | $-26.04M | $-31.89M | $-15.35M | $-14.68M | $-13.45M | $-4.13M | $-4.56M | $-15.54M | $-14.23M | $-70.96M | $-17.44M | $-14.95M | $-14.51M | $-37.10M | $-7.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -0.31% | 1.06% | 1.98% | 1.31% | 0.71% | 1.04% | 0.94% | 1.31% | 0.82% | 1.10% | 5.37% | 1.00% | 1.00% | 1.11% | 0.21% | 1.08% | 0.92% | 1.59% | 1.07% | 1.18% |
EyePoint Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EYPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
EyePoint Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 6 | 3 | 6 | 5 | 10 | 8 | 4 | 4 | 8 | 6 | 11 | 20 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $14.34M | $14.98M | $14.41M | $15.23M | $15.44M | $15.24M | $17.03M | $13.43M | $11.84M | $10.77M | $11.59M | $11.06M | $10.88M | $12.48M | $11.55M | $12.14M | $12.10M | $11.92M | $7.81M | $2.28M |
| Avg Forecast | $920.93K | $818.61K | $10.69M | $11.05M | $15.10M | $15.21M | $16.32M | $15.21M | $13.67M | $12.07M | $121.41M | $11.66M | $15.97M | $16.77M | $16.67M | $15.18M | $15.03M | $15.17M | $13.37M | $12.11M | $28.08M | $11.06M | $5.82M | $11.13M | $11.01M | $6.04M | $10.27M | $5.20M | $254.30K | $1.24M |
| High Forecast | $920.93K | $818.61K | $10.69M | $11.05M | $15.10M | $25.21M | $16.32M | $15.21M | $22.52M | $12.07M | $121.41M | $11.66M | $15.97M | $16.77M | $16.67M | $20.22M | $20.03M | $20.21M | $17.81M | $16.14M | $37.41M | $13.28M | $7.75M | $14.84M | $14.68M | $8.05M | $13.69M | $6.93M | $305.16K | $1.48M |
| Low Forecast | $920.93K | $818.61K | $10.69M | $11.05M | $15.10M | $8.78M | $16.32M | $15.21M | $1.08M | $12.07M | $121.41M | $11.66M | $15.97M | $16.77M | $16.67M | $11.52M | $11.41M | $11.52M | $10.15M | $9.20M | $21.32M | $8.85M | $4.42M | $8.46M | $8.36M | $4.59M | $7.80M | $3.95M | $203.44K | $989.69K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.12% | 1.28% | 0.90% | 0.91% | 0.93% | 1.00% | 1.13% | 0.89% | 0.89% | 0.89% | 0.41% | 1.00% | 1.87% | 1.12% | 1.05% | 2.01% | 1.18% | 2.29% | 30.70% | 1.84% |
EyePoint Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $12.07M, based on 5 Wall Street analysts, with a range of $12.07M to $12.07M. The forecast indicates a -15.85% fall compared to EYPT last annual SG&A of $14.34M (Jun 23).
EyePoint Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 6 | 3 | 6 | 5 | 10 | 8 | 4 | 4 | 8 | 6 | 11 | 20 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.61 | $-0.58 | $-1.72 | $-0.49 | $-0.53 | $-0.60 | $-0.64 | $-0.58 | $-0.35 | $-0.50 | $-1.07 | $-0.30 | $-1.04 | $-1.14 | $-0.98 | $-1.46 | $-1.08 | $-2.02 | $-4.41 | $-1.53 |
| Avg Forecast | $-0.88 | $-0.82 | $-0.71 | $-0.66 | $-0.61 | $-0.56 | $-0.50 | $-0.40 | $-0.49 | $-0.50 | $1.38 | $-0.68 | $-0.61 | $-0.68 | $-0.52 | $-0.58 | $-0.53 | $-0.40 | $-0.45 | $-0.49 | $-0.07 | $-0.30 | $-1.05 | $-0.95 | $-1.18 | $-1.38 | $-1.20 | $-1.37 | $-0.14 | $-0.11 |
| High Forecast | $-0.88 | $-0.82 | $-0.71 | $-0.66 | $-0.61 | $-0.43 | $-0.50 | $-0.40 | $-0.32 | $-0.50 | $1.38 | $-0.68 | $-0.61 | $-0.68 | $-0.52 | $-0.40 | $-0.36 | $-0.28 | $-0.31 | $-0.34 | $-0.05 | $-0.21 | $-0.72 | $-0.65 | $-0.81 | $-0.94 | $-0.82 | $-0.94 | $-0.11 | $-0.09 |
| Low Forecast | $-0.88 | $-0.82 | $-0.71 | $-0.66 | $-0.61 | $-0.72 | $-0.50 | $-0.40 | $-0.62 | $-0.50 | $1.38 | $-0.68 | $-0.61 | $-0.68 | $-0.52 | $-0.83 | $-0.76 | $-0.58 | $-0.64 | $-0.71 | $-0.10 | $-0.43 | $-1.50 | $-1.36 | $-1.68 | $-1.97 | $-1.72 | $-1.96 | $-0.17 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -0.44% | 0.85% | 2.82% | 0.72% | 1.01% | 1.04% | 1.21% | 1.44% | 0.78% | 1.01% | 15.66% | 1.00% | 0.99% | 1.20% | 0.83% | 1.06% | 0.90% | 1.48% | 31.50% | 13.91% |
According to undefined Wall Street analysts, EyePoint Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EYPT previous annual EPS of $NaN (undefined).
EyePoint Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VIRX | Viracta Therapeutics | $0.25 | $8.00 | 3100.00% | Buy |
| ALXO | ALX Oncology | $2.22 | $24.50 | 1003.60% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| SLS | SELLAS Life Sciences Group | $1.32 | $7.00 | 430.30% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| IPHA | Innate Pharma | $2.26 | $10.00 | 342.48% | Buy |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| EYPT | EyePoint Pharmaceuticals | $9.10 | $30.00 | 229.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
EYPT Forecast FAQ
Is EyePoint Pharmaceuticals a good buy?
Yes, according to 6 Wall Street analysts, EyePoint Pharmaceuticals (EYPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of EYPT's total ratings.
What is EYPT's price target?
EyePoint Pharmaceuticals (EYPT) average price target is $30 with a range of $30 to $30, implying a 229.67% from its last price of $9.1. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will EyePoint Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for EYPT stock, the company can go up by 229.67% (from the last price of $9.1 to the average price target of $30), up by 229.67% based on the highest stock price target, and up by 229.67% based on the lowest stock price target.
Can EyePoint Pharmaceuticals stock reach $14?
EYPT's average twelve months analyst stock price target of $30 supports the claim that EyePoint Pharmaceuticals can reach $14 in the near future.
What are EyePoint Pharmaceuticals's analysts' financial forecasts?
EyePoint Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $40.29M (high $46.81M, low $36.1M), average EBITDA is $-47.645M (high $-40.002M, low $-57.613M), average net income is $-108M (high $-97.402M, low $-120M), average SG&A $61.84M (high $71.84M, low $55.41M), and average EPS is $-2.076 (high $-1.947, low $-2.236). EYPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.3M (high $15.3M, low $15.3M), average EBITDA is $-15.3M (high $-15.3M, low $-15.3M), average net income is $-163M (high $-163M, low $-163M), average SG&A $23.48M (high $23.48M, low $23.48M), and average EPS is $-3.073 (high $-3.073, low $-3.073).
Did the EYPT's actual financial results beat the analysts' financial forecasts?
Based on EyePoint Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $41.4M, which missed the average analysts forecast of $42.08M by -1.61%. Apple's EBITDA was $-74.757M, beating the average prediction of $-53.317M by 40.21%. The company's net income was $-125M, beating the average estimation of $-95.912M by 29.82%. Apple's SG&A was $60.32M, missing the average forecast of $64.59M by -6.60%. Lastly, the company's EPS was $-3.34, beating the average prediction of $-2.388 by 39.87%. In terms of the last quarterly report (Jun 2023), EyePoint Pharmaceuticals's revenue was $9.1M, missing the average analysts' forecast of $79.1M by -88.49%. The company's EBITDA was $-22.761M, missing the average prediction of $-79.1M by -71.23%. EyePoint Pharmaceuticals's net income was $-22.92M, missing the average estimation of $73.64M by -131.13%. The company's SG&A was $14.34M, missing the average forecast of $121.41M by -88.19%. Lastly, the company's EPS was $-0.61, missing the average prediction of $1.38 by -144.08%